Pricing Log in Create free account

Compugen Ltd. (CGEN) vs Keros Therapeutics, Inc. (KROS)

Compugen Ltd. and Keros Therapeutics, Inc. are both Biotechnology companies. Compugen Ltd. and Keros Therapeutics, Inc. are of similar size ($185.7M and $183.7M). Keros Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Compugen Ltd. trades at 5.2×. Compugen Ltd. grew revenue faster over the last twelve months: 234.2% against −76.4%. Compugen Ltd. has the higher net margin (47.6% vs −112.2%) and the higher return on invested capital (0.00% vs −233.2%). Across the 18 metrics below, Compugen Ltd. leads on 13 and Keros Therapeutics, Inc. on 5.

Valuation

Metric CGEN KROS Biotechnology median
P/E 5.16 n/m 10.60
P/S 2.51 3.38 9.40
P/B 2.09 0.67 2.13
Price to free cash flow 4.63 n/m 25.18
EV/EBITDA 1.99 1.02 0.66
EV/Sales 0.81 (1.33) 9.02
Earnings yield 19.39% (30.02%) (32.88%)
Free cash flow yield 21.58% (25.93%) (23.13%)

Profitability

Metric CGEN KROS Biotechnology median
Gross margin 86.89% 100.00% 68.51%
Operating margin 40.94% (133.16%) 0.00%
Net margin 47.55% (112.18%) 0.00%
Free cash flow margin 54.10% (87.73%) 0.00%
Return on equity 47.85% (12.56%) (51.96%)
Return on assets 23.86% (11.76%) (46.06%)
Return on invested capital 0.00% (233.22%) 0.00%

Growth

Metric CGEN KROS Biotechnology median
Revenue growth (TTM) 234.18% (76.37%) 6.76%
EPS growth (last fiscal year) 337.50% 146.00% 29.88%
Revenue growth, 5-year CAGR 105.20% 89.45% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGEN KROS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.72 18.14 4.97
Net debt to EBITDA (4.65) (4.16) 1.01

Dividend

Metric CGEN KROS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CGEN KROS Biotechnology median
Market cap 185.67m 183.68m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack